SP-101 (Synphatec) Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.

N/A

Report date: 2026/01/14 20:00:44
NME

Base Information

Drug NameSP-101 (Synphatec) Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Drug Alias NameSP-101SP-101 (Synphatec)
ClassificationOther
Mechanisms of ActionGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsDepressive Disorder, Major
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesSleptek (Shanghai) Biopharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsDepressive Disorder, Major
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A